Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is well-positioned for revenue growth due to its advancing collaborations in the pharmaco-epigenetics space and the potential for strategic partnerships following the validation of its Nu.Q Lung Cancer Test. Additionally, the adoption of its Nu.Q Discover biomarkers by over 1,000 veterinary hospitals in Japan highlights strong market interest and expands its revenue potential in the animal diagnostics sector. The company’s proprietary Nucleosomics platform not only enhances research capabilities but also accelerates biomarker discovery, contributing positively to its overall financial outlook.

Bears say

VolitionRX Ltd. is actively working on developing blood tests using its Nucleosomics platform, specifically targeting the high false-positive rates associated with low-dose computed tomography (LDCT) screenings for pulmonary nodules. However, the reliance on addressing these prevalent diagnostic issues does not guarantee successful market adoption or revenue generation, particularly when faced with competition and existing alternative diagnostic methods. Financially, the company's challenge lies in translating research and development into commercially viable products, amid uncertainties surrounding regulatory approval and potential market penetration.

Volitionrx Limited (VNRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.